InMode Ltd. (INMD) Earnings Call Transcript & Summary

Good day and welcome to the InMode Ltd Fourth Quarter and Full Year 2021 Earnings Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Miri Segal from MS-IR. Please go ahead.

Thank you, operator and everyone for joining us today. Welcome to InMode's fourth quarter and full year 2021 earnings call. Before we begin, I would like to remind our listeners, that certain information provided on this call, may contain forward-looking statements and the safe harbor statement outlined in today's earnings release, also pertains to this call. If you have not received a copy of the release, please go to the Investor Relations section of the company's website. Changes in business, competitive, technological, regulatory and other factors, could cause actual results to differ materially from those expressed by the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. Such we can give no assurance as to the accuracy, forward-looking statements and assume no obligation to update them, except as required by law. With that, I'd like to pass the call over to Moshe Mizrahy, Chairman and CEO. Moshe, Please go ahead.

Thank you, Miri and thank you all for joining our fourth quarter and full year 2021 earnings call. With me today are Dr. Michael Kreindel, our Co-founder and Chief Technology Officer; Yair Malca, our CFO; Shakil Lakhani, our President in North America; Dr. Spero Theodorou, our Chief Medical Officer; and Rafael Lickerman, our VP of Finance. We will all be available for Q&A session after our prepared remarks. Once again we have the pleasure of announcing a record quarter with revenue of 110.5 and $357.6 million for full year, an increase of 47% and 73%, compared to the same period last year, crossing the $100 million quarterly revenue mark a symbolic and meaningful achievement for our company. We continue to achieve strong profitable growth. Net income for the quarter --- was a GAAP basis was 52.7 and $55.2 million on a non-GAAP basis. In the full year of 2021, net income reached $165 million on a GAAP basis, and $176.3 million on a non-GAAP basis. As a result of our strategy, to focus on selling more system globally, sales of capital equipment represent 89% of our total revenue in the fourth quarter. Sales from consumable and services increased significantly and reached record volume every quarter. This sale accounted for 11% of total in the fourth quarter and in the full year 2021. By launching new platforms and innovative modalities and growth and growing our installed base in the US and globally, we expect consistent growth in consumable revenue will become a more significant part of our revenue mix. I would like to highlight their ongoing growth from our minimally invasive and ablative technologies, which now account for 73% of our revenue, compared with 65% last year. Hands-Free devices generated 17% of our revenue, and non-invasive RF and laser platforms represent the remaining 10%. The broader client mix for the full year was 72% for minimally invasive, 20% for Hands-Free and 8% for non-invasive RF and laser platforms. Looking at the international side of the business, fourth-quarter sales outside the US, accounted for $36.3 million, a 69% increase compared to the same quarter last year. Full year results which $120 million --- $120.3 million, a 112% increase compared to 2020. These figures represent 34% of our total revenue of all 2021 and 33% of our total revenue for the fourth quarter. InMode currently operate in 71 countries, having added 17 countries more in 2021. We also expanded our existing operation in Italy, by establishing a subsidiary there. We see most of the growth coming from region, where we are already involved, yet there was opportunity in the new territories. Furthermore, despite facing serious global supply chain obstacle in 2021, we successfully delivered every system within 10 days of receiving the order. We would not have done that without our hardworking and dedicated employees and partners. We value their contribution and thank them for it. As for 2022, we're continuing to evaluate the impact of the Omicron and the BA2 COVID variant on our business that we do in every territory. We hope that current wave of COVID will pass and will be the last one. So that business across the world will return to normal soon. Now I would like to turn the call over to Shakil, our President in North America. Shakil?

Thanks, Moshe and everyone for joining us. InMode ended the fourth quarter and 2021 with another record performance. And the successful launches of the EvolveX and EmpowerRF platforms. Sales from capital equipment was the main contributor to our quarterly revenues with $98.6 million in Q4 and $319.2 million for all of 2021, with an installed base of 11,600 units. Additionally, as Moshe mentioned, as our installed base grows and our systems are used more frequently, the number of disposables continues to reach new records as well. The US remains the leading market and was the biggest contributor to our topline. With the total fourth-quarter sales amounting to $74.2 million, compared to $53.7 million in the same quarter of 2020, of 38% increase. Despite new COVID variant, causing another surge across North America, physician offices in the fourth quarter, we are the busiest they've been and all of 2021. Demand for minimally invasive technologies has been steadily increasing, supporting our growth in the US and globally. With the launch of EmpowerRF, we've seen significant interest by physicians in the women's health space. Currently, our focus is on North America, however, we will gradually expand to the rest of the world. We plan to continue hiring new sales staff in the North American market, which will increase topline growth, as proven in previous years. We're very grateful to our team and their continued commitment, we'll not be as successful, as we are without each and every individual. I will now hand over the call to Yair for a review of the financial results in more detail. Yair?

Thanks, Shakil, and good day everyone. Now I'd like to break down the numbers for the quarter, and the year in greater detail. Total revenue in the fourth quarter of 2021, increased 47% year-over-year to $110.5 million, with gross margin of 85% on a GAAP basis. For full year 2021, revenue totalled $357.6 million, an increase of 73%, compared to 2020. Sales of minimally invasive and subdermal ablative technologies in the fourth quarter of 2021, grew 64% year-over-year. The geographic revenue mix in Q4 was 67% in the US, and 33% internationally, compared to 71% and 29% for the same quarter in 2020 respectively. International sales increased year-over-year by 69%. Capital equipment in the fourth quarter accounted for 89% of our revenue, and consumable and service revenues are presented the remaining 11%, identical to the ratio for the full year. GAAP operating expenses in the fourth quarter were 39.5 and $136.5 million for the full year of 2021, a 35% and 33% increase year-over-year, respectively. Sales and marketing expenses increased 40% in Q4, compared to the fourth quarter of 2020 and 38% for the full year 2021, compared to last year. This is the result of the improvement in the COVID status, in certain countries and regions around the world, especially in the US, where we saw an increase in in-person marketing events. Share-based compensation decreased to $3.1 million in the fourth quarter of 2021 compared to $3.2 million in the fourth quarter of 2020, and to $12 million for all of 2021 from $12.8 million in all of 2020. On a non-GAAP basis, operating expenses totaled approximately $37.5 million in Q4 2021, compared to operating expenses of $26 million in the same quarter of 2020, an increase of 44%. Non-GAAP operating expenses for the full year of 2021 were $126.4 million, compared to $90 million in the full year of 2020, a 40% increase. GAAP operating margin was 49% in the fourth quarter, and 47% for all of 2021 compared to 47% and 35% for the same periods in 2020. Non-GAAP operating margin was 51% in the fourth quarter and 50% for all of 2021 compared to 51% and 42% for the same periods in 2020. Profitability in the quarter and during 2021 was remarkable. GAAP diluted earnings per share for Q4 2021 were $0.61 compared to $0.43 per diluted share in the fourth quarter of 2020. And $1.92 for the full year of 2021, compared to $0.89 --- excuse me, for the full year of 2020. Non-GAAP diluted earnings per share for Q4 2021 were $0.64, compared to $0.47 per diluted share in the fourth quarter of 2020, and $2.05 for the full year of 2021, compared to $1.06 for the full year of 2020. We ended 2021 with a very strong balance sheet. As of December 31, 2021, the company had cash and cash equivalents, marketable securities and deposits of $415.9 million. On the cash flow front, the company generated $52.9 million from operating activities for the fourth quarter, and $174.9 million for all of 2021. I will now turn over the call back to Moshe.

Thank you, everybody. I believe we now open the Q&A session. Operator?

[Operator Instructions] Our first question today comes from Matt Taylor with UBS.

So I wanted to -- excuse me -- you mentioned Omicron in the press release and in your comments. And I guess, I just wanted to get some thoughts from you about how disruptive that has been in Q1, has that had any impact on your views for the rest of the year and any color on recent?

Yes. This is Moshe. Hi Matt. Well, I cannot answer what would be the effect on the full year. But one thing I can tell you, that right now, there are some countries, which are totally close and we have some slowdown, for example in China. I'm sure you know that they have adapted a zero cases program. They don't allow people to travel even within their territory. They don't allow people to travel between cities. So our salespeople in China right now, are very limited in the way they can do business. They try to overcome it. Also in Europe their countries are under lockdown, like Netherlands and Austria, where hopefully soon they will get out of it. I believe that sometime in February or maybe early March, business will go back to normal. But we continue, as I said, to evaluate the situation, country by country, territory by territory. You know we are lucky that it is not affecting the United State as of now. But with the Omicron and the new variant that just came, which create another, you know, feel in some countries, we will see, what will happen.

Okay. Thanks, Moshe. Just to clarify, I mean, you guys are now in dozens of countries, you just mentioned a few. What percentage of your revenue base in these -- there are actually having more severe lockdowns?

Well, China is one of our growth engine. And I believe that in the first quarter, we will do less than what we did on the fourth quarter, hopefully not much less. I would say that 10% of the countries where we sell, will be some effect. Other than that, we need to wait and see what will happen in the next few weeks.

And then, I wanted to ask one about margins and supply chain it seems like you've been doing a good job, you're managing through these challenges, keeping your margins really high here. Is there anything that investors should be concerned about, in terms of disruption or increased costs and how conservative are you being are here, your margin guidance for 2022?

Well, we manage it very well, the situation in 2021, as we go into the supply chain. I'm sure, you know that, you know, some -- we have established a red team in Israel. But every time we had a problem with component and with sub-assembly, we managed to overcome it because we have more than one supplier per each component at each sub-assembly. Things are not getting better, that's something that I can tell you right away. The supply chain is not improving. I don't say it's getting worse. But as we see now, the beginning of 2022, we still see some difficulties and we foresee that during 2022, it will continue. I can give you an example of logistic. A container from Israel to North America used to cost $3500, now the cost is $12,000. But we managed to overcome it by doing some kind of special shipping in the lower cost. Well, I believe, we will overcome the supply chain, like we did in 2021. And we deliver everything within a week or 10 days of every order. We do our best. But I know from some of our competitors and some of other companies in the medical field, that they are giving now delivery time to customers of 6 and 9 months, we did not do that. But, yes, we are flexible, and I would say that, hopefully, it will not affect us.

Okay. Maybe just have one more, I'd like to ask one on the pipeline and more of a clinical, I mean for Spero. Would just love some thoughts on Empower, if you're still feeling like $20 million or $25 million, I think you've talked about, is a good number for '22, and maybe talk about some of the data that you're generating around it, and whether that could develop into more kind of medical applications from Empower in the future?

I'll let Moshe handle the first part of that question to [ Shak ].

Well, if the question is whether or not, we will do what we anticipated for 2022, which is worldwide to $20 million. I think, yes, I think we will do it, North America and we intend to introduce the platforms in other parts or other territories as well. But I think Spero what Matt asked is about the clinical data.

Sure. Thank you, Matt. Great question. We're always very conservative when we're discussing female health involvements and because, obviously, the standards there, as opposed to esthetics are a little different. However, we did do a soft launch and we're getting feedback continuously across the country for a number of urogynecologists and gynecologists. As you know urogynecologists are the group, that is probably the most critical and the toughest group to penetrate. This just wasn't plastic surgery, and this is where we started, and because we believe, we have a product that has a lot of staying power and we wanted them to buy-in and adopt and help us and sort of guide us through this process. And I can tell you right now, that the results have been very, very encouraging. They're extremely excited. We have ways to go absolutely. But the preliminary data, just coming back is pretty remarkable. Typically, we look at a number of treatments and some of the data that shows that we go one to 3 treatments, typically for what this new devices doing especially, as it regards to vaginal -- intravaginal microneedling. And we wanted to see how far we can push things, just with one treatment. And we saw that the results are very, very strong, and we're very, very happy to see that our preliminary results are coming back in this fashion. Now, as you know, Matt, this is not --- this is a marathon and we're always very conservative on the way we look at our data, and the way we present it. But I can tell you right now, the excitement is palpable. And I'm very, very happy to say that, and Shakil will probably reiterate the same thing that, feedback and excitement across the board is something that we're very, very happy to have. And I'll leave it at that for now. But because a lot of the things that we're doing in the midst of publication, as you know. So everything we do is peer-reviewed, everything we try to put out there is going to be published. And our adoption rate for KOLs is we always take the hard way first, as you know, and that pays us dividends. So urogynecologist, toughest group, we have some of the top KOL leaders in the country, and we're just continuing doing studies with them, and opening the doors with this group. And I can tell you right now, they're very excited. So, I can leave it at that.

The next question comes from Kyle Rose with Canaccord.

Great. Moshe, you talked -- you talked a lot about the growth in the consumable side, and with the installed base you have expectations for that to continue to grow. Can you maybe just kind of help us flush that out a little bit more? I mean, does that mean you expect to see consumables and service revenues go from 11% to 12% next year, does that mean it could we see it move closer towards 15%. Just trying to really understand what that looks like, now that you've got over 11,000 systems placed globally.

Well, I can tell you that -- this is Moshe. I can tell you that in the last quarter, we sold 132,000 disposables. Compared to the third quarter, where we sold only 94,000. So this is growing. But as long, as we continue to install or to enlarge our installed base and, by the way, in the fourth quarter we sold more than 1,300 system. So it's -- went up from 10% to 11%. With the installed base of 11,600 system, that's what we have right now in the market, we have something like, I would say, close to more than 500,000 disposable every year. And don't forget, not all the system that we sell needed disposable, I would say that a little bit more than 50% or 55% maybe 60% are using disposable and go all the way to the subdermal fat. As we grow, all of our new platforms are designed to have disposable. We will not design additional platforms without any disposables. So in the future, once the installed base will get, I would say 20,000 or 25,000. I assume that the disposable will grow to a neighborhood of, I would say, 40%, 50% of the total revenue. But again, I would like to say it again, we are not razor and razorblade company. We do not sell the system for less or would do not give the system for free, just to charge high price for disposable. We know that some companies in the medical esthetic did in the past and they failed. And therefore, we charge for the system, and we price the disposable in a reasonable price in order to encourage doctor to use more and more, and to have more treatment. I think this is the right approach and the right philosophy, and this is, basically, our strategy.

Great. I appreciate the color there. And I think we've already gotten some good insight on Empower, maybe I wondering if you could get some commentary understood, the launch of EvolveX, just what you're seeing there, whether it's upgrades from existing customers or continued penetration from new customers there, maybe just commentary on that launch will be helpful?

Shakil, can you answer that?

Yes, sure. Absolutely. So we've actually seen some -- the combination of RF and EMS type of device, we're basically seeing a very -- it's not -- I know you had mentioned that if it was existing customers or not, there are some, that are -- we're going to be doing some upgrades for some of our existing customers, so they have the latest and greatest technology. But, as in terms of the newer business with the market, we have an extremely aggressive plan put in place for -- as you know, Spero even just mentioned with Empower and also with Evolve, we always kind of slow both things to make sure that things are ready to excel from an efficacy standpoint, a safety standpoint, and also from a result standpoint. So now that we're very comfortable with that, we've -- although we use the word launches for both Empower and for EvolveX, now we're going into the hard launch phase, which we feel pretty optimistic about, both from the business perspective for our customers and also from our standpoint as well. So we do see -- we've seen some excitement, the results so far have been, Spero can elaborate a little more, but the results so far have been very impressive, safety has been very impressive. So overall we're feeling pretty good about it. Spero, do you want to talk a little about [indiscernible].

Great. I mean, sure. Look -- when you look at incontinence in these things, and you look at the standard that's been up to now, sort of if you could get a 50% improvement at 3 months, I think that benchmark is quite low. And it's just a function of what's the technologies out there currently -- 50% improvement being like women that loses urine and do these things, that's what you can expect. And I think that, if we took that as a goal and then we went after that as a goal to hit that, sort of 50% benchmark in 3 months, I don't think we would be in business. We're taking everything that we do from the aesthetics and Mishka will also say the following that, we will not go to market, unless we have something like a producer an 85%, 90% clinical result, because simply put, people will not pay cash for it and we're in the cash business. So we're taking all of that model. We're taking all that sort of thought process and we're applying it to the female health and wellness sector. So we need to -- and I can tell you right now, our preliminary results are blowing past that number. So past the 50% of 3 months, which is currently out there. So we're very, very encouraged in that respect. But that is our standard, we need to be able to say, if someone is coming in, for a clinical treatment. That is not currently covered by an insurance and is paying cash for it, that patient needs to be able to say, okay, I have an 80% to 90% of improvement. And I can tell you right now, that's the area we're looking at, and that's what we're getting right now as a feedback from our doctors and we're looking at the data and we're very excited that we're actually, blowing past that benchmark. I am very cautious always, because these things are numbers, but so far, that's the range that we're getting, or it's really high as comparable to what we get into esthetics and excited to keep on moving this direction. So we thank Moshe for the support he's giving us, but that is our benchmark and we want to redefine the way, things are being addressed in this space in female health and wellness, and I think we're well off on the road to do that.

Sure. Can you talk a little bit of EvolveX?

Sure. So I mean it's important to understand that when it comes to radio frequency and heating and muscle and all that sort of thing, we were the first to actually, look at that space and I can tell you this much, Shakil and I were talking about this is like, well, how about we are pre-heating the muscle, just as you work out and, there's a whole history of heating the muscle on rehabilitation for athletes, injured athletes. So the ability to be able to pre-heat the muscle and then activated with CMS, is something that we started doing early on. And we did that because it's a function of our different handpieces, right. We have a RF handpiece, we have the MS piece. So taking that ability and bring it over to EvolveX and saying, okay, now we have a handpiece that can do both at the same time is great, but you could also uncouple it. What does that mean? Well, not every -- everybody different, everyone's requirement is different. So having the ability to change things around, to be able to come and say, well, what do you want? Do you want to -- want your muscles bigger or you want the fat gone? Because there are people who say, okay, I don't need the fat, all this fat or I don't want to have loose volume in my butt, for example. So all these things, the more any device or any platform that respects the individuality and the change in body habits, is a very patient, and you're able to change things around like that, is great, right, because everyone is sort of unique. Transform in EvolveX does that. So I could -- I could do RF with EMS, preheat the muscle and then activate it. I could do EMS on itself, I could do RF in itself, so that is sort of the way we look at things in plastic surgery. When we do minimally invasive and invasive surgery. We brought that over to non-invasive. And that ability to change things around to couple, uncouple is sort of something that Mishka was great at delivering and we find big residence in our customer base to be able to do that as well, because this is mimicking real life in the way clinical results are being addressed.

Next question comes from Michael Matson with Needham & Company.

Yes. Wanted to ask about the EPS guidance, by my math, it seems to -- I understand there's a tax rate headwind, but it does seem to apply that there is operating margin decline in 2021 or sorry, from 2021 if my math is correct. So is there any reason to expect that or just being conservative on your part?

So we always trying to be conservative, as you know. In addition, we do plan to invest more in sales and marketing and some more marketing activities as well as clinical studies. And so this year we expect to have a slightly higher operating expenses. But overall we are looking at 48% operating margin, it's still quite remarkable, and adding to that around 2022 going to be the first year, as you know, that we start paying taxes after 10 year break. And that's -- would come out to be at around 10%. We, estimated at this point at least. And as I mentioned, we always tend to be conservative when we can.

Okay, got it. And then, your cash balance continues to grow here. You know the stock has pulled back quite a bit, arguably overvalue -- sorry, undervalued, maybe when you look at it on a P/E basis. So would you be open to doing a share repurchase?

Well, Mike, we did. So far, we did close to 1.5 million shares that we bought back in the last, I would say, less than a year. We still have a way to go. The Board of Director gave us the permission to continue to buy back shares and we will continue. I'm not saying that we will spend $200 million for that, but we'll do it -- we'll do it on a daily basis. Yes, you're right, we have more than $400 million in cash, close to $420 million in cash. We are exploring some opportunities for M&A, but, we did -- we did not find anything that will fit our portfolio yet. One thing I can tell you, as we said before, we will not buy a laser company because laser is becoming a commodity in the medical esthetic. We need to find something that will complement our portfolio either in technology, marketing and sales network, something that will 2 plus 2 will equal 5, but in -- nowadays is very difficult to find something with a reasonable price. But, yet we have a very robust R&D pipeline, close to 15 project, and we're releasing 2 project every year. So, the organic growth will continue to be the most, I would say growth engine for InMode in the -- at least in the next 2 years.

Okay, got it. And then just looking at the different product categories, the Hands-Free, it looks like it's been down year-over-year for 2 quarters in a row. I mean I would assume that's mainly just due to the comps from COVID where that was kind of benefiting back in 2020 and non -- conversely, non-invasive has been strengthening recently, maybe that's a similar issue and kind of opposite directions easier comps, but I was just curious if there is anything else going on there aside from the comps in those 2 categories?

Well, the Hands-Free -- when we came up with the Hands-Free to the market, we knew that this is not going to be more than 20% of our business. Our main category is minimally invasive and ablative, where we can take operations from the surgical, from the full surgery and the full anesthesia and bring it to the doctor office. This is exactly what the Empower is doing. And the Empower is a minimal invasive because you basically penetrate the skin and you do some fractional RF as well. And we will continue to develop product that will have on one hand will be more surgical than non-surgical and on the hand and we'll have some disposable as well. So Hands-Free is a complementary technology for us. It is not going to be 50% of our business. The non-invasive RF and the laser, which I call it as a commodity category, we have a lot of competition for many companies. This is not the main category for us and it is good because it's a very competitive market with a very low gross margin with overcapacity, with price per unit, which is much lower than what we can charge. Without any IP protection, laser are invented 40-something years ago, there was no IP protection anymore and therefore we try to concentrate on where we have competitive advantage. And this is a -- this is basically the surgical part of our business. And I believe that we're very happy with the breakdown on the category where more than 70% are in the area where we can protect the technology and get nice prices for the system. 20% will be the Hands-Free and I hope it will continue. We're going to bring to the market second generation of the Hands-Free devices. And the laser and the regular -- the regular RF, the non-invasive RF, will continue to be between 8% to 10% of our business, that kind of breakdown will be continued in the future.

The next question comes from Jeff Johnson with Baird.

Maybe just a couple of clarifying or follow-up questions on things that have been discussed so far. So Moshe just your comment there on the Hands-Free, I mean and trying to put that together with I think it was Shak's comments on EvolveX. You know as EvolveX hopefully ramp some this year, do Hands-Free continue to decline year-over-year for the next couple of quarters until we kind of anniversary through those 4 really, really tough comps or just how to think about the year-over-year performance of Hands-Free just in the next couple of few quarters.

No, we did not say that it will go down. The only thing they said it will remain, something like between 18% to 20% of our total business. But as the business will grow the Hands-Free will also will grow. I mean, the transform and EvolveX is the second generation of the Evolve. And hopefully in 2022 we will bring second generation for the [ Evoke ] for the face Hands-Free as well, just to maintain the competitive advantage. I mean the fact that we came up with EMS and RF combined in the same modality, give us a major competitive advantage vis-a-vis all the other companies that in the Hands-Free currently. So I don't think the free will go down, it will continue to be a complementary technology for the doctors. But to tell you that that will be more than 20% of our total business. I will say, I don't think it will be, it will maintain the same level and the same, I would say, percentage as part of the total portfolio.

Okay. That's helpful. And just going back on Empower, look I understand you guys are cash paid business, it's a fantastic place to be from a consumer-facing standpoint, things like that. But if some of those urinary incontinence and urinary loss or urine loss numbers are as good as they are, and even if the path might be extended, a couple of few years it would take to get actual reimbursement, would there ever be a reason to go down the path of trying to get a reimbursement code? It would seem like it would open the market up so much more. And if the effect is so strong, it would seem like would be good for the patient as well. So just how to think about reimbursement, commercial pay, government pay versus cash pay for something like an Empower procedure on UI.

Let me try to answer, and I will hand it out to Spero maybe will elaborate more. We're not against reimbursement. We never said that. I mean, in the future, we will continue to develop some indication for women health, which are, which might need reimbursement. As of today, the Empower, with the 4 modalities, Forma V, the Morpheus8 V, [ V Tone ] and Aviva, we feel like private money, it's the best. I would say business model for this platforms. To tell you that in the future, we will not go into reimbursement indication, we might go. And we're developing some indication like that today.

Moshe, that's a great question by the way. So a lot of companies will spend a lot of time going down the reimbursement pathway and not having any revenue at all. And a one point hoping at some point after you burned through all that cash, but at some point able to go down that route. And whether -- and getting breakthrough designation as we all know is very hard to do. But I can tell you this much that, absolutely we want to change the way women's health is being done. And we have -- we're in the unique position to have -- to have cash-based procedures that to support our research, to support indications, to support FDA, all of those things, that we can do this in parallel. That's a unique position to be in. All this data that we're collecting, everything that we're looking at, the types of KOLs we're bringing on board, the type of academic establishments that we're engaging, it's all building the foundation for them in the future. So, yes, we're not opposed on the contrary, we wanted to be able to open the market. But we are in the unique position to be able to do these things with a cash-based foundation, which is quite different than most companies out there, is sort of pass or fail in the -- in as far as when they're doing these sort of things. Does that answer your question?

It does. Thank you. That's helpful. And then last one, I promise, Just on the competition side, Moshe, I mean I totally agree with you, [ docs ] do not like paying quick fees or per use fees, I think the model as much as investors want to see more recurring revenue. I totally get the model of charging a full, market price for the system itself and lower price for the consumable that's surely what those doctors appreciate. But on the competitive side, there is some noise out there from a company that had some good skin tightening data, but they are charging a very high consumable price as well. So one, are -- just kind of help us understand the competition in my skin tightening right now, with this newer competitor that has good skin tightening data, but the consumables are high?

Well, I assume you talk about Thermage, which is, we've sold -- they just announced that they're going public, and they released their prospectus. And in their prospectus, yes, they have 3 quarters, something like, I don't know, 75% disposable and 25% platforms. But don't forget, Thermage is a 25 years old company. They're on the market for long time. We are on the market only 5 or 6 years, 20% of the time of the 25 years that they are. So they have a bigger installed base and they said less platforms and they sell more consumable. I think that one day, we will sell more consumable, and it will be much higher than 10%. But it's take time to build the installed base worldwide. Once the installed base will be much larger than what we have today, and I assume Thermage has much more than 10,000 system worldwide installed, especially in Asia -- especially in Asia, where there are very strong 70% of the business is in Asia, I believe that we will also see some, that our disposable proportion of the total revenue will be higher. But right now we're still young company. And as a young company with only 11,000 system installed, I mean the revenue coming from the disposable is growing and is growing. It went from 10% to 11%. But don't expect that to go to 20% over 3 quarter. It will -- it will go slowly, but it will go nicely, we see more and more treatment are being done. We see more and more disposable are being -- both from us. But in the same time, we see a lot of new platforms that we install in the market and the new doctors need some time before they start doing 10 cases per week. So this is a learning curve. We all [ ride ] on the learning curve and one day, we will be not -- I don't want to say like, like some time, like too much, but the disposal will be a bigger part of our revenue.

And maybe we can take it offline, in the follow-up call, Moshe. I was actually referring to a different company, the Renuvion helium procedure. But, again, maybe in the interest of time, we can just talk offline.

We're happy to send you an article, where we did a comparison study with them, so it just got published last week.

Yes. Of course, of course. He's talking about J Plasma, I understand, okay.

This concludes our Question-and-Answer Session. I would now like to turn the conference back over to Moshe Mizrahy for any closing remarks.

Thank you, operator. Thank you. Thank you all for joining our fourth quarter 2021 and the full year 2021 earning call. I want to take the opportunity to thank all of our people around the world in all of the 72 countries -- 71 countries that we operate in. I want to thank the salespeople. I want to take the engineering team for working very hard, special thanks for the logistic and manufacturing and the supply chain people that managed to supply everything on time, in a tough year like 2021. And I'm sure that they will continue to do that. Thank you all and see you soon in the next earning call.

This conference has now concluded. Thank you for attending today's presentation. You may now disconnect.